Written by ι Stock Market Media Group Staff — October 22, 2013
Nuvilex, Inc. (OTCQB: NVLX) and its subsidiary, Medical Marijuana Sciences, Inc., received another validation of their efforts to bring research utilizing cannabidiol (CBD) as the basis for developing treatments for some of the deadliest forms of cancer to the industry. This latest study serves as another piece of evidence in a mounting argument that cannabinoids from Cannabis, such as CBD, are effective anti-cancer drugs.
It was a team at St George’s, University of London that provided the latest data which was published in the journal Anticancer Research. Dr. Wai Liu and his colleagues carried out laboratory investigations that used a number of cannabinoids, either alone or in combination with each other, to measure their anti-cancer actions in relation to leukemia.
The team studied six cannabinoids and each demonstrated anti-cancer properties as effective as those seen with tetrahydrocannabinol (THC), and, of note, they found the cannabinoids had an increased effect on cancer cells when combined with each other.
This group’s research has shown that the non-hallucinogenic components of Cannabis can act as effective anti-cancer agents. The anti-cancer properties of THC, the primary hallucinogenic component of Cannabis, have been recognized for many years, but research into similar Cannabis-derived compounds has been somewhat limited.
Dr Liu who led the team of researchers said, “This study is a critical step in unpicking the mysteries of cannabis as a source of medicine. The cannabinoids examined have minimal, if any, hallucinogenic side effects, and their properties as anti-cancer agents are promising.”
He added, “These agents are able to interfere with the development of cancerous cells, stopping them in their tracks and preventing them from growing. In some cases, by using specific dosage patterns, they can destroy cancer cells on their own.”
Nuvilex established Medical Marijuana Sciences to study the medical applications of marijuana and will use its expertise, current research and its success in the biotechnology sector in an effort to make the subsidiary among the leaders in the industry. As the company’s COO, Dr. Gerald Crabtree, has said, Medical Marijuana Sciences will initially focus on pancreatic cancer and cancers of the brain – specifically glioblastomas. He says as more of these studies come to light, it further validates the subsidiary’s choice of non-psychoactive CBD as the initial basis on which to develop treatments for two of the deadliest forms of cancer.
This latest research is part of a growing portfolio of studies into the medicinal properties of Cannabis by the research team at St George’s. Dr. Liu says the next step will be to examine these compounds in combination with existing anti-cancer treatments and study treatment schedules to identify strategies that will maximize their efficacy.
He says, “Used in combination with existing treatments, we could discover some highly effective strategies for tackling cancer. Significantly, these compounds are inexpensive to produce and making better use of their unique properties could result in much more cost effective anti-cancer drugs in future.”
In commenting on the study, Dr. Crabtree stated “The study by Dr. Liu and colleagues adds to the ever-growing list of evidence that validates the activity of cannabinoids, particularly CBD, against various types of cancer. It is not only a testament to our company’s choice of CBD as a basis on which to develop treatments for cancer, but also is in agreement with the opinion of others, such as Dr. Sanjay Gupta, CNN’s Chief Medical Correspondent, who believes that CBD-rich rather than THC-rich Cannabis should be used for the treatment of serious diseases.”